After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for DENTSPLY SIRONA Inc. (XRAY) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.79, or -2.57%, to $29.99. Volume reached 1,734,377 shares, with price reaching a high of $30.85 and a low of $29.55. Earlier, Yahoo Finance discussed this stock as it revealed Dentsply Sirona Appoints Glenn Coleman as Chief Financial Officer.
XRAY belongs to the Healthcare sector of the NASDAQ while operating in the Medical Instruments & Supplies industry. At the end of the last regular session, the stock closed at $29.55 and fluctuated between $30.63 as its day high and $29.41 as its day low. The current market capitalization of DENTSPLY SIRONA Inc. is $6.55B. A total of 3.83 million shares were traded on the day, compared to an average of 1.90M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, XRAY has seen 11 BUY and 2 SELL insider trades, representing the acquisition of 329 and the disposition of 243 shares. Over the last 12 months, there were 105 BUYs and 51 SELLs from insiders. Insiders purchased 698,883 shares during that period but sold 415,301.
In the most recent transaction, BRANDT ERIC sold 6,900 shares of XRAY for 39.71 per share on May 03. After the transaction, the Director now owns 35,155 company shares. In a previous transaction on Dec 01, Casey Donald M Jr. bought 20,000 shares at 49.78 per share. XRAY shares that President & CEO owns now total 52,500.
Among the insiders who sold shares, Yankie Lisa disposed of 1,903 shares on Nov 19 at a per-share price of $52.63. This resulted in the Sr VP & Chief HR Officer holding 21,825 shares of XRAY after the transaction. In another insider transaction, Petersohn Walter sold 86,431 shares at $54.18 per share on Nov 17. Company shares held by the Chief Commercial Officer now total 25,740.
Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. DENTSPLY SIRONA Inc. pays an annual dividend of $0.50, resulting in a dividend yield of 1.69%, and it has a price to earnings (P/E) ratio of 17.58. XRAY’s most recent ex-dividend date was 09/29/2022 when it declared a $0.125 quarterly dividend that was paid in cash on 10/14/2022. Previously, the company paid the dividend on 07/08/2022 with an ex-dividend date of 06/23/2022. The dividend was $0.125 per share in cash.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for XRAY in the last 3 months, the mean price target is $42.50 with high estimates of $51.00 and low estimates of $38.00. In terms of 52-week highs and lows, XRAY has a high of $61.18 and a low of $30.58.
As of this writing, XRAY has an earnings estimate of $0.54 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of $0.6 per share and a lower estimate of $0.49. The company reported an EPS of $0.52 in the last quarter, which was 4% higher than expectations of $0.5.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XRAY is Overweight with a score of 3.45. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.